US2023405087A9PendingUtilityA9
Acylated glp-1/glp-2 dual agonists
Est. expiryDec 9, 2036(~10.4 yrs left)· nominal 20-yr term from priority
A61K 38/26C07K 14/605A61P 3/04A61P 3/10A61K 38/00A61K 47/542A61P 3/06A61P 3/08A61P 1/00A61P 1/04A61P 1/16A61P 1/12
71
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
Claims
exact text as granted — not AI-modified1 . A method of prophylaxis or treatment of
(a) malabsorption, ulcers, short-bowel syndrome, cul-de-sac syndrome, inflammatory bowel disease, irritable bowel syndrome, pouchitis, celiac sprue, tropical sprue, hypogammaglobulinemic sprue, mucositis induced by chemotherapy or radiation therapy, diarrhea induced by chemotherapy or radiation therapy, low grade inflammation, metabolic endotoxemia, necrotising enterocolitis, primary biliary cirrhosis, hepatitis, fatty liver disease, or gastrointestinal side-effects of inflammatory conditions in a subject in need thereof, or (b) obesity, morbid obesity, obesity-linked gallbladder disease, obesity-induced sleep apnea, inadequate glucose control, glucose tolerance, dyslipidaemia, diabetes, pre-diabetes, metabolic syndrome or hypertension in a subject in need thereof; the method comprising administering a glucagon-like-peptide 1/glucagon-like-peptide 2 (GLP-1/GLP-2) dual agonist, or pharmaceutically acceptable salt thereof, to the subject, wherein the GLP-1/GLP-2 dual agonist is represented by the formula:
R 1 —X*—U—R 2 ,
wherein: R 1 is hydrogen (Hy), C 1-4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl; R 2 is NH 2 or OH; X* is a peptide of formula I:
(I)
(SEQ ID NO: 3)
H-X2-EG-X5-F-X7-X8-E-X10-X11-TIL-X15-X16-X17-A-
X19-X20-X21-FI-X24-WL-X27-X28-X29-KIT-X33,
wherein:
X2 is Aib or G;
X5 is T or S;
X7 is T or S;
X8 is S, E or D;
X10 is L, M, V or ψ;
X11 is A, N or S;
X15 is D or E;
X16 is G, E, A or ψ;
X17 is Q, E, K, L or ψ;
X19 is A, V or S;
X20 is R, K or ψ;
X21 is D, L or E;
X24 is A, N or S;
X27 is I, Q, K, H or Y;
X28 is Q, E, A, H, Y, L, K, R or S;
X29 is H, Y or Q;
X33 is D or E;
U is absent or a sequence of 1-15 residues, each, independently, selected from K, k, E, A, T, I, L and ψ;
the molecule contains one and only one ψ, wherein ψ is a residue of K, k, R, Orn, Dap or Dab in which the side chain is conjugated to a substituent having the formula Z 1 — or Z 1 —Z 2 —, wherein
Z 1 — is CH 3 —(CH 2 ) 10-22 —(CO)— or HOOC—(CH 2 ) 10-22 —(CO)—; and
Z 2 — is selected from —Z S1 —, —Z S1 —Z S2 —, —Z S2 —Z S1 —, —Z S2 —, —Z S3 —, —Z S1 —Z S3 —, —Z S2 —Z S3 —, —Z S3 —Z S1 —, —Z S3 —Z S2 —, —Z S1 —Z S2 —Z S3 —, —Z S1 —Z S3 —Z S2 —, —Z S2 —Z S1 —Z S3 —, —Z S2 —Z S3 —Z S1 —, —Z S3 —Z S1 —Z S2 —, —Z S3 —Z S2 —Z S1 —, or —Z S2 —Z S3 —Z S2 —;
wherein
Z S1 is isoGlu, β-Ala, isoLys, or 4-aminobutanoyl;
Z S2 is -(Peg3) m -, wherein m is 1, 2, or 3; and
Z S3 is a peptide sequence of 1-6 amino acid residues independently selected from the group consisting of A, L, S, T, Y, Q, D, E, K, k, R, H, F and G;
and wherein at least one of X5 and X7 is T.
2 . The method of claim 1 , wherein
(a) the ulcers are peptic ulcers, Zollinger-Ellison Syndrome, drug-induced ulcers, or ulcers related to infections or other pathogens; and/or (b) the inflammatory bowel disease is Crohn's disease or ulcerative colitis; and/or (c) the celiac sprue arises from gluten induced enteropathy or celiac disease; and/or (d) the fatty liver disease is parenteral nutrition associated gut atrophy, PNALD (Parenteral Nutrition-Associated Liver Disease), NAFLD (Non-Alcoholic Fatty Liver Disease), or NASH (Non-Alcoholic Steatohepatitis); and/or (e) the gastro-intestinal side-effects of inflammatory conditions are pancreatitis or graft versus host disease (GVHD); and/or (f) the dyslipidemia is elevated LDL levels or reduced HDL/LDL ratio; and/or (g) the diabetes is Type 2 diabetes or gestational diabetes.
3 . The method of claim 1 , wherein in the GLP-1/GLP-2 dual agonist:
X2 is Aib or G; X5 is T or S; X7 is T or S; X8 is S; X10 is L or ψ; X11 is A or S; X15 is D or E; X16 is G, E, A or ψ; X17 is Q, E, K, L or ψ; X19 is A or S; X20 is R or ψ; X21 is D, L or E; X24 is A; X27 is I, Q, K or Y; X28 is Q, E, A, H, Y, L, K, R or S; X29 is H, Y or Q; and X33 is D or E.
4 . The method of claim 1 , wherein in the GLP-1/GLP-2 dual agonist:
(a) X5 is S and X7 is T, or X5 is T and X7 is T; and/or (b) X11 is A and X15 is D, or X11 is S and X15 is E, or X11 is A and X15 is E; and/or (c) X16 is E and X17 is Q, or X16 is ψ and X17 is Q, E, K or L, or X16 is G and X17 is ψ; and/or (d) X21 is D; and/or (e) X27 is I; and/or (f) X29 is H, or X28 is A and X29 is H, or X28 is E and X29 is H, or X29 is Q, or X27 is Q and X29 is Q.
5 . The method of claim 1 , wherein in the GLP-1/GLP-2 dual agonist the residues at X27-X29 consist of a sequence selected from:
IQH; IEH IAH; IHH; IYH; ILH; IKH; IRH; ISH; QQH; YQH; KQH; IQQ; IQY; and IAY.
6 . The method of claim 1 , wherein in the GLP-1/GLP-2 dual agonist X* is a peptide of formula II:
(II)
(SEQ ID NO: 4)
H-X2-EG-X5-F-X7-SELATILD-X16-X17-AAR-X21-FIAWLI-
X28-X29-KITD,
wherein:
X2 is Aib or G;
X5 is T or S;
X7 is T or S;
X16 is G or ψ;
X17 is Q, E, K, L or ψ;
X21 is D or L;
X28 is Q, E, A, H, Y, L, K, R or S; and
X29 is H, Y or Q.
7 . The method of claim 1 , wherein in the GLP-1/GLP-2 dual agonist X* is a peptide of formula III:
(III)
(SEQ ID NO: 5)
H[Aib]EG-X5-F-X7-SE-X10-ATILD-X16-X17-AA-X20-X21-
FIAWLI-X28-X29-KITD,
wherein:
X5 is T or S;
X7 is T or S;
X10 is L or ψ;
X16 is G, E, A or ψ;
X17 is Q, E, K, L or ψ;
X20 is R or ψ;
X21 is D or L;
X28 is E, A or Q;
X29 is H, Y or Q;
and at least one of X5 and X7 is T.
8 . The method of claim 1 , wherein in the GLP-1/GLP-2 dual agonist X* is a peptide of formula IV:
(IV)
(SEQ ID NO: 6)
H[Aib]EG-X5-F-X7-SELATILD-X16-X17-AAR-X21-FIAWLI-
X28-X29-KITD,
wherein:
X5 is T or S;
X7 is T or S;
X16 is G or ψ;
X17 is E, K, L or ψ;
X21 is D or L;
X28 is E or A;
X29 is H, Y or Q;
and at least one of X5 and X7 is T.
9 . The method of claim 1 , wherein in the GLP-1/GLP-2 dual agonist X16 is ψ and X17 is E, K or L.
10 . The method of claim 9 , wherein in the GLP-1/GLP-2 dual agonist:
X21 is D and X28 is E; X21 is D and X28 is A; X21 is L and X28 is E; or X21 is L and X28 is A.
11 . The method of claim 1 , wherein in the GLP-1/GLP-2 dual agonist X* is a peptide of formula V:
(V)
(SEQ ID NO: 7)
H[Aib]EG-X5-F-X7-SELATILD-Ψ-QAARDFIAWLI-X28-X29-
KITD,
wherein:
X5 is T or S;
X7 is T or S;
X28 is Q, E, A, H, Y, L, K, R or S;
X29 is H, Y or Q;
and at least one of X5 and X7 is T.
12 . The method of claim 1 , wherein in the GLP-1/GLP-2 dual agonist ψ is a Lys residue whose side chain is conjugated to the substituent Z 1 — or Z 1 —Z 2 —.
13 . The method of claim 1 , wherein in the GLP-1/GLP-2 dual agonist Z 1 — is selected from the group consisting of
dodecanoyl;
tetradecanoyl;
hexadecanoyl;
octadecanoyl;
eicosanoyl;
13-carboxytridecanoyl, i.e. HOOC—(CH 2 ) 12 —(CO)—;
15-carboxypentadecanoyl, i.e. HOOC—(CH 2 ) 14 —(CO)—;
17-carboxyheptadecanoyl, i.e. HOOC—(CH 2 ) 16 —(CO)—;
19-carboxynonadecanoyl, i.e. HOOC—(CH 2 ) 18 —(CO)—; and
21-carboxyheneicosanoyl, i.e. HOOC—(CH 2 ) 20 —(CO)—.
14 . The method of claim 1 , wherein in the GLP-1/GLP-2 dual agonist —Z 2 — is absent.
15 . The method of claim 1 , wherein in the GLP-1/GLP-2 dual agonist —Z 2 — comprises Z S1 .
16 . The method of claim 15 , wherein in the GLP-1/GLP-2 dual agonist Z S1 is isoGlu.
17 . The method of claim 15 , wherein in the GLP-1/GLP-2 dual agonist —Z 2 — has the formula —Z S1 —Z S3 —Z S2 —, and wherein Z S1 is bonded to Z 1 and Z S2 is bonded to the side chain of the amino acid component of ψ.
18 . The method of claim 1 , wherein in the GLP-1/GLP-2 dual agonist —Z 2 — is:
isoGlu(Peg3) 0-3 ;
β-Ala(Peg3) 0-3 ;
isoLys(Peg3) 0-3 ;
4-aminobutanoyl(Peg3) 0-3 ; or
isoGlu-KEK-(Peg3) 0-3 .
19 . The method of claim 1 , wherein in the GLP-1/GLP-2 dual agonist Z 1 — or Z 1 —Z 2 — is:
[17-carboxy-heptadecanoyl]-isoGlu-;
[17-carboxy-heptadecanoyl]-isoGlu-KEK-Peg3- (SEQ ID NO: 413);
[17-carboxy-heptadecanoyl]-isoGlu-Peg3-;
[19-carboxy-nonadecanoyl]-isoGlu-;
[19-carboxy-nonadecanoyl]-isoGlu-KEK- (SEQ ID NO: 541);
[19-carboxy-nonadecanoyl]-isoGlu-KEK-Peg3- (SEQ ID NO: 414);
[19-carboxy-nonadecanoyl]-isoGlu-KEK-Peg3-Peg3- (SEQ ID NO: 434);
[19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3-;
[19-carboxy-nonadecanoyl]-isoLys-Peg3-Peg3-Peg3-;
[hexadecanoyl]-βAla-;
[hexadecanoyl]-isoGlu-; or
octadecanoyl-.
20 . The method of claim 19 , wherein in the GLP-1/GLP-2 dual agonist ψ is:
K([17-carboxy-heptadecanoyl]-isoGlu).
K([17-carboxy-heptadecanoyl]-isoGlu-KEK-Peg3) (SEQ ID NO: 542);
K([17-carboxy-heptadecanoyl]-isoGlu-Peg3);
K([19-carboxy-nonadecanoyl]-isoGlu);
K([19-carboxy-nonadecanoyl]-isoGlu-KEK) (SEQ ID NO: 543);
K([19-carboxy-nonadecanoyl]-isoGlu-KEK-Peg3) (SEQ ID NO: 544);
K([19-carboxy-nonadecanoyl]-isoGlu-KEK-Peg3-Peg3) (SEQ ID NO: 545);
K([19-carboxy-nonadecanoyl]-isoGlu-Peg3-Peg3);
K([19-carboxy-nonadecanoyl]-isoLys-Peg3-Peg3-Peg3);
K([hexadecanoyl]-βAla-;
K([hexadecanoyl]-isoGlu); or
K(octadecanoyl).
21 . The method of claim 1 , wherein, in the GLP-1/GLP-2 dual agonist, U
(a) is 1-10 amino acids in length; and/or (b) comprises at least one charged amino acid selected from K, k, E, R, and Orn; and/or (c) comprises at least 1 positively charged amino acid and at least one negatively charged amino acid; and/or (d) is a chain of alternately positively and negatively charged amino acids.
22 . The method of claim 1 , wherein, in the GLP-1/GLP-2 dual agonist, U comprises residues selected only from K, k, E and ψ.
23 . The method of claim 22 , wherein, in the GLP-1/GLP-2 dual agonist, U is selected from the group consisting of K 3 (SEQ ID NO: 565), K 4 (SEQ ID NO: 566), K 5 (SEQ ID NO: 567), K 6 (SEQ ID NO: 568), K 7 (SEQ ID NO: 569), k 3 (SEQ ID NO: 573), k 4 (SEQ ID NO: 574), k 5 (SEQ ID NO: 575), k 6 (SEQ ID NO: 10), k 7 (SEQ ID NO: 576), KEK (SEQ ID NO: 8), EKEKEK (SEQ ID NO: 9), EkEkEk (SEQ ID NO: 11), AKAAEK (SEQ ID NO: 12), AKEKEK (SEQ ID NO: 13), ATILEK (SEQ ID NO: 14), K 1-14 -ψ (SEQ ID NO: 546), K 1-9 -ψ (SEQ ID NO: 547), K 1-6 -ψ (SEQ ID NO: 548), k 1-14 -ψ (SEQ ID NO: 554), k 1-9 -ψ (SEQ ID NO: 555), k 1-6 -ψ (SEQ ID NO: 55), KEψ (SEQ ID NO: 15), EKEKEψ (SEQ ID NO: 16), EkEkEψ (SEQ ID NO: 17), AKAAEψ (SEQ ID NO: 18), AKEKEψ (SEQ ID NO: 19), and ATILEψ (SEQ ID NO: 20).
24 . The method of claim 1 , wherein, in the GLP-1/GLP-2 dual agonist, U is absent.
25 . The method of claim 1 , wherein in the GLP-1/GLP-2 dual agonist:
(a) R 1 is Hy; or (b) R 2 is OH; or (c) R 1 is Hy and R 2 is OH.
26 . The method of claim 1 , wherein in the GLP-1/GLP-2 dual agonist X* or X*—U consists of the sequence:
(SEQ ID NO: 21)
H[Aib]EGTFSSELATILDΨEAARDFIAWLIEHKITD;
(SEQ ID NO: 22)
H[Aib]EGSFTSELATILDΨEAARDFIAWLIEHKITD;
(SEQ ID NO: 23)
H[Aib]EGTFTSELATILDΨEAARDFIAWLIEHKITD;
(SEQ ID NO: 24)
H[Aib]EGTFSSELATILDΨKAARDFIAWLIEHKITD;
(SEQ ID NO: 25)
H[Aib]EGSFTSELATILDΨKAARDFIAWLIEHKITD;
(SEQ ID NO: 26)
H[Aib]EGTFTSELATILDΨKAARDFIAWLIEHKITD;
(SEQ ID NO: 27)
H[Aib]EGTFSSELATILDGΨAARDFIAWLIEHKITD;
(SEQ ID NO: 28)
H[Aib]EGSFTSELATILDGΨAARDFIAWLIEHKITD;
(SEQ ID NO: 29)
H[Aib]EGTFTSELATILDGΨAARDFIAWLIEHKITD;
(SEQ ID NO: 30)
H[Aib]EGTFSSELATILDΨLAARDFIAWLIEHKITD;
(SEQ ID NO: 31)
H[Aib]EGSFTSELATILDΨLAARDFIAWLIEHKITD;
(SEQ ID NO: 32)
H[Aib]EGTFTSELATILDΨLAARDFIAWLIEHKITD;
(SEQ ID NO: 33)
H[Aib]EGTFSSELATILDΨLAARDFIAWLIAHKITD;
(SEQ ID NO: 34)
H[Aib]EGSFTSELATILDΨLAARDFIAWLIAHKITD;
(SEQ ID NO: 35)
H[Aib]EGTFTSELATILDΨLAARDFIAWLIAHKITD;
(SEQ ID NO: 36)
H[Aib]EGTFTSELATILDΨEAARLFIAWLIEHKITD;
(SEQ ID NO: 37)
H[Aib]EGTFSSELATILDΨQAARDFIAWLIQHKITD;
(SEQ ID NO: 38)
H[Aib]EGSFTSELATILDΨQAARDFIAWLIQHKITD;
(SEQ ID NO: 39)
H[Aib]EGTFTSELATILDΨQAARDFIAWLIQHKITD;
(SEQ ID NO: 40)
H[Aib]EGTFSSELATILDΨQAARDFIAWLIEHKITD;
(SEQ ID NO: 41)
H[Aib]EGTFSSELATILDΨQAARDFIAWLIAHKITD;
(SEQ ID NO: 42)
H[Aib]EGSFTSELATILDΨQAARDFIAWLIAHKITD;
(SEQ ID NO: 43)
H[Aib]EGTFTSELATILDΨQAARDFIAWLIAHKITD;
(SEQ ID NO: 44)
H[Aib]EGSFTSELATILDΨQAARDFIAWLIEHKITD;
(SEQ ID NO: 45)
H[Aib]EGTFTSELATILDΨQAARDFIAWLIEHKITD;
(SEQ ID NO: 46)
H[Aib]EGSFTSELATILDΨQAARDFIAWLIHHKITD;
(SEQ ID NO: 47)
H[Aib]EGSFTSELATILDΨQAARDFIAWLIYHKITD;
(SEQ ID NO: 48)
H[Aib]EGSFTSELATILDΨQAARDFIAWLILHKITD;
(SEQ ID NO: 49)
H[Aib]EGSFTSELATILDΨQAARDFIAWLIKHKITD;
(SEQ ID NO: 50)
H[Aib]EGSFTSELATILDΨQAARDFIAWLIRHKITD;
(SEQ ID NO: 51)
H[Aib]EGSFTSELATILDΨQAARDFIAWLISHKITD;
(SEQ ID NO: 52)
H[Aib]EGSFTSELATILDΨQAARDFIAWLQQHKITD;
(SEQ ID NO: 53)
H[Aib]EGSFTSELATILDΨQAARDFIAWLYQHKITD;
(SEQ ID NO: 54)
H[Aib]EGSFTSELATILDΨQAARDFIAWLKQHKITD;
(SEQ ID NO: 55)
H[Aib]EGSFTSELATILDΨQAARDFIAWLIQQKITD;
(SEQ ID NO: 56)
H[Aib]EGSFTSELATILDΨQAARDFIAWLIQYKITD;
(SEQ ID NO: 57)
H[Aib]EGTFSSELSTILEΨQASREFIAWLIAYKITE;
(SEQ ID NO: 58)
H[Aib]EGTFSSELATILDEQAARDFIAWLIAHKITDkkkkkΨ;
(SEQ ID NO: 59)
H[Aib]EGTFTSELATILDEQAARDFIAWLIAHKITDkkkkkΨ;
(SEQ ID NO: 60)
H[Aib]EGSFTSELATILDEQAARDFIAWLIEHKITDkkkkkΨ;
(SEQ ID NO: 61)
H[Aib]EGSFTSEΨATILDEQAARDFIAWLIEHKITD;
(SEQ ID NO: 62)
H[Aib]EGSFTSELATILEGΨAARDFIAWLIEHKITD;
(SEQ ID NO: 63)
H[Aib]EGSFTSELATILDEQAAΨDFIAWLIEHKITD;
(SEQ ID NO: 64)
H[Aib]EGTFTSELATILDEQAAΨDFIAWLIEHKITD;
(SEQ ID NO: 65)
H[Aib]EGTFTSEΨATILDEQAARDFIAWLIEHKITD;
(SEQ ID NO: 66)
H[Aib]EGSFTSELATILDAΨAARDFIAWLIEHKITD;
or
(SEQ ID NO: 67)
H[Aib]EGSFTSELATILDAKAAΨDFIAWLIEHKITD.
27 . The method of claim 26 , wherein in the GLP-1/GLP-2 dual agonist X* or X*—U consists of the sequence:
(SEQ ID NO: 68)
H[Aib]EGTFSSELATILD[K*]EAARDFIAWLIEHKITD;
(SEQ ID NO: 69)
H[Aib]EGSFTSELATILD[K*]EAARDFIAWLIEHKITD;
(SEQ ID NO: 70)
H[Aib]EGTFTSELATILD[K*]EAARDFIAWLIEHKITD;
(SEQ ID NO: 71)
H[Aib]EGTFSSELATILD[K*]KAARDFIAWLIEHKITD;
(SEQ ID NO: 72)
H[Aib]EGSFTSELATILD[K*]KAARDFIAWLIEHKITD;
(SEQ ID NO: 73)
H[Aib]EGTFTSELATILD[K*]KAARDFIAWLIEHKITD;
(SEQ ID NO: 74)
H[Aib]EGTFSSELATILDG[K*]AARDFIAWLIEHKITD;
(SEQ ID NO: 75)
H[Aib]EGSFTSELATILDG[K*]AARDFIAWLIEHKITD;
(SEQ ID NO: 76)
H[Aib]EGTFTSELATILDG[K*]AARDFIAWLIEHKITD;
(SEQ ID NO: 77)
H[Aib]EGTFSSELATILD[K*]LAARDFIAWLIEHKITD;
(SEQ ID NO: 78)
H[Aib]EGSFTSELATILD[K*]LAARDFIAWLIEHKITD;
(SEQ ID NO: 79)
H[Aib]EGTFTSELATILD[K*]LAARDFIAWLIEHKITD;
(SEQ ID NO: 80)
H[Aib]EGTFSSELATILD[K*]LAARDFIAWLIAHKITD;
(SEQ ID NO: 81)
H[Aib]EGSFTSELATILD[K*]LAARDFIAWLIAHKITD;
(SEQ ID NO: 82)
H[Aib]EGTFTSELATILD[K*]LAARDFIAWLIAHKITD;
(SEQ ID NO: 83)
H[Aib]EGTFTSELATILD[K*]EAARLFIAWLIEHKITD;
(SEQ ID NO: 84)
H[Aib]EGTFSSELATILD[K*]QAARDFIAWLIQHKITD;
(SEQ ID NO: 85)
H[Aib]EGSFTSELATILD[K*]QAARDFIAWLIQHKITD;
(SEQ ID NO: 86)
H[Aib]EGTFTSELATILD[K*]QAARDFIAWLIQHKITD;
(SEQ ID NO: 87)
H[Aib]EGTFSSELATILD[K*]QAARDFIAWLIEHKITD;
(SEQ ID NO: 88)
H[Aib]EGTFSSELATILD[K*]QAARDFIAWLIAHKITD;
(SEQ ID NO: 89)
H[Aib]EGSFTSELATILD[K*]QAARDFIAWLIAHKITD;
(SEQ ID NO: 90)
H[Aib]EGTFTSELATILD[K*]QAARDFIAWLIAHKITD;
(SEQ ID NO: 91)
H[Aib]EGSFTSELATILD[K*]QAARDFIAWLIEHKITD;
(SEQ ID NO: 92)
H[Aib]EGTFTSELATILD[K*]QAARDFIAWLIEHKITD;
(SEQ ID NO: 93)
H[Aib]EGSFTSELATILD[K*]QAARDFIAWLIHHKITD;
(SEQ ID NO: 94)
H[Aib]EGSFTSELATILD[K*]QAARDFIAWLIYHKITD;
(SEQ ID NO: 95)
H[Aib]EGSFTSELATILD[K*]QAARDFIAWLILHKITD;
(SEQ ID NO: 96)
H[Aib]EGSFTSELATILD[K*]QAARDFIAWLIKHKITD;
(SEQ ID NO: 97)
H[Aib]EGSFTSELATILD[K*]QAARDFIAWLIRHKITD;
(SEQ ID NO: 98)
H[Aib]EGSFTSELATILD[K*]QAARDFIAWLISHKITD;
(SEQ ID NO: 99)
H[Aib]EGSFTSELATILD[K*]QAARDFIAWLQQHKITD;
(SEQ ID NO: 100)
H[Aib]EGSFTSELATILD[K*]QAARDFIAWLYQHKITD;
(SEQ ID NO: [[(]]101)
H[Aib]EGSFTSELATILD[K*]QAARDFIAWLKQHKITD;
(SEQ ID NO: 102)
H[Aib]EGSFTSELATILD[K*]QAARDFIAWLIQQKITD;
(SEQ ID NO: 103)
H[Aib]EGSFTSELATILD[K*]QAARDFIAWLIQYKITD;
(SEQ ID NO: 104)
H[Aib]EGTFSSELSTILE[K*]QASREFIAWLIAYKITE;
(SEQ ID NO: 105)
H[Aib]EGTFSSELATILDEQAARDFIAWLIAHKITDkkkkk[k*];
(SEQ ID NO: 106)
H[Aib]EGTFTSELATILDEQAARDFIAWLIAHKITDkkkkk[k*];
(SEQ ID NO: 107)
H[Aib]EGSFTSELATILDEQAARDFIAWLIEHKITDkkkkk[k*];
(SEQ ID NO: 108)
H[Aib]EGSFTSE[K*]ATILDEQAARDFIAWLIEHKITD;
(SEQ ID NO: 109)
H[Aib]EGSFTSELATILEG[K*]AARDFIAWLIEHKITD;
(SEQ ID NO: 110)
H[Aib]EGSFTSELATILDEQAA[K*]DFIAWLIEHKITD;
(SEQ ID NO: 111)
H[Aib]EGTFTSELATILDEQAA[K*]DFIAWLIEHKITD;
(SEQ ID NO: 112)
H[Aib]EGTFTSE[K*]ATILDEQAARDFIAWLIEHKITD;
(SEQ ID NO: 113)
H[Aib]EGSFTSELATILDA[K*]AARDFIAWLIEHKITD;
or
(SEQ ID NO: 114)
H[Aib]EGSFTSELATILDAKAA[K*]DFIAWLIEHKITD;
wherein K* or k* indicates an L or D lysine residue respectively in which the side chain is conjugated to the substituent Z 1 — or Z 1 —Z 2 —.
28 . The method of claim 1 , wherein in the GLP-1/GLP-2 dual agonist X* or X*—U consists of the sequence:
(SEQ ID NO: 115)
H[Aib]EGTFSSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]EAARDFIAWLIEHKITD;
(SEQ ID NO: 116)
H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]EAARDFIAWLIEHKITD;
(SEQ ID NO: 117)
H[Aib]EGTFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]EAARDFIAWLIEHKITD;
(SEQ ID NO: 118)
H[Aib]EGTFSSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]KAARDFIAWLIEHKITD;
(SEQ ID NO: 119)
H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]KAARDFIAWLIEHKITD;
(SEQ ID NO: 120)
H[Aib]EGTFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]KAARDFIAWLIEHKITD;
(SEQ ID NO: 121)
H[Aib]EGTFSSELATILDG[K([17-carboxy-heptadecanoyl]-isoGlu)]AARDFIAWLIEHKITD;
(SEQ ID NO: 122)
H[Aib]EGSFTSELATILDG[K([17-carboxy-heptadecanoyl]-isoGlu)]AARDFIAWLIEHKITD;
(SEQ ID NO: 123)
H[Aib]EGTFTSELATILDG[K([17-carboxy-heptadecanoyl]-isoGlu)]AARDFIAWLIEHKITD;
(SEQ ID NO: 124)
H[Aib]EGTFSSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]LAARDFIAWLIEHKITD;
(SEQ ID NO: 125)
H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]LAARDFIAWLIEHKITD;
(SEQ ID NO: 126)
H[Aib]EGTFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]LAARDFIAWLIEHKITD;
(SEQ ID NO: 127)
H[Aib]EGTFSSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]LAARDFIAWLIAHKITD;
(SEQ ID NO: 128)
H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]LAARDFIAWLIAHKITD;
(SEQ ID NO: 129)
H[Aib]EGTFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]LAARDFIAWLIAHKITD;
(SEQ ID NO: 130)
H[Aib]EGTFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]EAARLFIAWLIEHKITD;
(SEQ ID NO: 131)
H[Aib]EGTFSSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIQHKITD;
(SEQ ID NO: 132)
H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIQHKITD;
(SEQ ID NO: 133)
H[Aib]EGTFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIQHKITD;
(SEQ ID NO: 134)
H[Aib]EGTFSSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIEHKITD;
(SEQ ID NO: 135)
H[Aib]EGTFSSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIAHKITD;
(SEQ ID NO: 136)
H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIAHKITD;
(SEQ ID NO: 137)
H[Aib]EGTFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIAHKITD;
(SEQ ID NO: 138)
H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIEHKITD;
(SEQ ID NO: 139)
H[Aib]EGTFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIEHKITD;
(SEQ ID NO: 140)
H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIHHKITD;
(SEQ ID NO: 141)
H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIYHKITD;
(SEQ ID NO: 142)
H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLILHKITD;
(SEQ ID NO: 143)
H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIKHKITD;
(SEQ ID NO: 144)
H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIRHKITD;
(SEQ ID NO: 145)
H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLISHKITD;
(SEQ ID NO: 146)
H[Aib]EGSFTSELATILD[K([Hexadecanoyl]-βAla)]QAARDFIAWLQQHKITD;
(SEQ ID NO: 147)
H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]iso-Glu-
Peg3)]QAARDFIAWLYQHKITD;
(SEQ ID NO: 148)
H[Aib]EGSFTSELATILD[K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-
Peg3)]QAARDFIAWLKQHKITD;
(SEQ ID NO: 149)
H[Aib]EGSFTSELATILD[K([19-carboxy-nonadecanoyl]iso-Lys-Peg3-Peg3-
Peg3)]QAARDFIAWLIQQKITD;
(SEQ ID NO: 150)
H[Aib]EGSFTSELATILD[K(Octadecanoyl)]QAARDFIAWLIQYKITD;
(SEQ ID NO: 151)
H[Aib]EGTFSSELSTILE[K(Hexadecanoyl-isoGlu)]QASREFIAWLIAYKITE ;
(SEQ ID NO: 152)
H[Aib]EGTFSSELATILDEQAARDFIAWLIAHKITDkkkkkk([17-carboxy-Heptadecanoyl]-
IsoGlu)];
(SEQ ID NO: 153)
H[Aib]EGTFTSELATILDEQAARDFIAWLIAHKITDkkkkkk([17-carboxy-Heptadecanoyl]-
IsoGlu)];
(SEQ ID NO: 154)
H[Aib]EGSFTSELATILDEQAARDFIAWLIEHKITDkkkkkk([17-carboxy-Heptadecanoyl]-
IsoGlu)];
(SEQ ID NO: 155)
H[Aib]EGTFTSELATILD[K([19-carboxy-nonadecanoyl]-isoGlu)]QAARDFIAWLIQHKITD;
(SEQ ID NO: 156)
H[Aib]EGSFTSE[K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-
Peg3)]ATILDEQAARDFIAWLIEHKITD;
(SEQ ID NO: 157)
H[Aib]EGSFTSELATILD[K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-
Peg3)]KAARDFIAWLIEHKITD;
(SEQ ID NO: 158)
H[Aib]EGSFTSELATILEG[K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-
Peg3)]AARDFIAWLIEHKITD;
(SEQ ID NO: 159)
H[Aib]EGSFTSELATILDEQAA[K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-
Peg3)]DFIAWLIEHKITD;
(SEQ ID NO: 160)
H[Aib]EGTFTSELATILDEQAA[K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-
Peg3)]DFIAWLIEHKITD;
(SEQ ID NO: 161)
H[Aib]EGTFSSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu-KEK-
Peg3)]QAARDFIAWLIQHKITD;
(SEQ ID NO: 162)
H[Aib]EGTFSSELATILD[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]QAARDFIAWLIQHKITD;
(SEQ ID NO: 163)
H[Aib]EGTFSSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu-KEK-
Peg3)]QAARDFIAWLIEHKITD;
(SEQ ID NO: 164)
H[Aib]EGTFSSELATILD[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]QAARDFIAWLIEHKITD;
(SEQ ID NO: 165)
H[Aib]EGTFTSELATILD[K([19-carboxy-nonadecanoyl]-isoGlu-
KEK)]QAARDFIAWLIQHKITD;
(SEQ ID NO: 166)
H[Aib]EGTFTSELATILD[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]QAARDFIAWLIQHKITD;
(SEQ ID NO: 167)
H[Aib]EGSFTSE[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]ATILDEQAARDFIAWLIEHKITD;
(SEQ ID NO: 168)
H[Aib]EGTFTSE[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]ATILDEQAARDFIAWLIEHKITD;
(SEQ ID NO: 169)
H[Aib]EGSFTSE[K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-
Peg3)]ATILDEQAARDFIAWLIEHKITD;
(SEQ ID NO: 170)
H[Aib]EGTFTSELATILD[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]QAARDFIAWLIEHKITD;
(SEQ ID NO: 171)
H[Aib]EGSFTSELATILD[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]QAARDFIAWLIEHKITD;
(SEQ ID NO: 172)
H[Aib]EGSFTSELATILD[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]QAARDFIAWLIAHKITD;
(SEQ ID NO: 173)
H[Aib]EGSFTSELATILD[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]KAARDFIAWLIEHKITD;
(SEQ ID NO: 174)
H[Aib]EGSFTSELATILD[K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-
Peg3)]QAARDFIAWLIEHKITD;
(SEQ ID NO: 175)
H[Aib]EGSFTSELATILEG[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]AARDFIAWLIEHKITD;
(SEQ ID NO: 176)
H[Aib]EGSFTSELATILDA[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]AARDFIAWLIEHKITD;
(SEQ ID NO: 177)
H[Aib]EGSFTSELATILDA[K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-
Peg3)]AARDFIAWLIEHKITD;
(SEQ ID NO: 178)
H[Aib]EGSFTSELATILDEQAA[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]DFIAWLIEHKITD;
(SEQ ID NO: 179)
H[Aib]EGTFTSELATILDEQAA[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]DFIAWLIEHKITD;
(SEQ ID NO: 180)
H[Aib]EGSFTSELATILDEQAA[K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-
Peg3)]DFIAWLIEHKITD;
(SEQ ID NO: 181)
H[Aib]EGTFTSELATILDEQAA[K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-
Peg3)]DFIAWLIEHKITD;
or
(SEQ ID NO: 182)
H[Aib]EGSFTSELATILDAKAA[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]DFIAWLIEHKITD.
29 . The method of claim 1 , wherein the GLP-1/GLP-2 dual agonist is:
(SEQ ID NO: 183)
Hy-H[Aib]EGTFSSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]EAARDFIAWLIEHKITD-
OH (Compound 1);
(SEQ ID NO: 184)
Hy-H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]EAARDFIAWLIEHKITD-
OH (Compound 2);
(SEQ ID NO: 185)
Hy-H[Aib]EGTFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]EAARDFIAWLIEHKITD-
OH (Compound 3);
(SEQ ID NO: 186)
Hy-H[Aib]EGTFSSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]KAARDFIAWLIEHKITD-
OH (Compound 4);
(SEQ ID NO: 187)
Hy-H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]KAARDFIAWLIEHKITD-
OH (Compound 5);
(SEQ ID NO: 188)
Hy-H[Aib]EGTFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]KAARDFIAWLIEHKITD-
OH (Compound 6);
(SEQ ID NO: 189)
Hy-H[Aib]EGTFSSELATILDG[K([17-carboxy-heptadecanoyl]-isoGlu)]AARDFIAWLIEHKITD-
OH (Compound 7);
(SEQ ID NO: 190)
Hy-H[Aib]EGSFTSELATILDG[K([17-carboxy-heptadecanoyl]-isoGlu)]AARDFIAWLIEHKITD-
OH (Compound 8);
(SEQ ID NO: 191)
Hy-H[Aib]EGTFTSELATILDG[K([17-carboxy-heptadecanoyl]-isoGlu)]AARDFIAWLIEHKITD-
OH (Compound 9);
(SEQ ID NO: 192)
Hy-H[Aib]EGTFSSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]LAARDFIAWLIEHKITD-
OH (Compound 10);
(SEQ ID NO: 193)
Hy-H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]LAARDFIAWLIEHKITD-
OH (Compound 11);
(SEQ ID NO: 194)
Hy-H[Aib]EGTFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]LAARDFIAWLIEHKITD-
OH (Compound 12);
(SEQ ID NO: 195)
Hy-H[Aib]EGTFSSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]LAARDFIAWLIAHKITD-
OH (Compound 13);
(SEQ ID NO: 196)
Hy-H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]LAARDFIAWLIAHKITD-
OH (Compound 14);
(SEQ ID NO: 197)
Hy-H[Aib]EGTFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]LAARDFIAWLIAHKITD-
OH (Compound 15);
(SEQ ID NO: 198)
Hy-H[Aib]EGTFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]EAARLFIAWLIEHKITD-
OH (Compound 16);
(SEQ ID NO: 199)
Hy-H[Aib]EGTFSSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIQHKITD-
OH (Compound 17);
(SEQ ID NO: 200)
Hy-H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIQHKITD-
OH (Compound 18);
(SEQ ID NO: 201)
Hy-H[Aib]EGTFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIQHKITD-
OH (Compound 19);
(SEQ ID NO: 202)
Hy-H[Aib]EGTFSSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIEHKITD-
OH (Compound 20);
(SEQ ID NO: 203)
Hy-H[Aib]EGTFSSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIAHKITD-
OH (Compound 21);
(SEQ ID NO: 204)
Hy-H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIAHKITD-
OH (Compound 22);
(SEQ ID NO: 205)
Hy-H[Aib]EGTFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIAHKITD-
OH (Compound 23);
(SEQ ID NO: 206)
Hy-H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIEHKITD-
OH (Compound 24);
(SEQ ID NO: 207)
Hy-H[Aib]EGTFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIEHKITD-
OH (Compound 25);
(SEQ ID NO: 208)
Hy-H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIHHKITD-
OH (Compound 26);
(SEQ ID NO: 209)
Hy-H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIYHKITD-
OH (Compound 27);
(SEQ ID NO: 210)
Hy-H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLILHKITD-
OH (Compound 28);
(SEQ ID NO: 211)
Hy-H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIKHKITD-
OH (Compound 29);
(SEQ ID NO: 212)
Hy-H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLIRHKITD-
OH (Compound 30);
(SEQ ID NO: 213)
Hy-H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu)]QAARDFIAWLISHKITD-
OH (Compound 31);
(SEQ ID NO: 214)
Hy-H[Aib]EGSFTSELATILD[K([Hexadecanoyl]-βAla)]QAARDFIAWLQQHKITD-OH
(Compound 32);
(SEQ ID NO: 215)
Hy-H[Aib]EGSFTSELATILD[K([17-carboxy-heptadecanoyl]iso-Glu-
Peg3)]QAARDFIAWLYQHKITD-OH (Compound 33);
(SEQ ID NO: 216)
Hy-H[Aib]EGSFTSELATILD[K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-
Peg3)]QAARDFIAWLKQHKITD-OH (Compound 34);
(SEQ ID NO: 217)
Hy-H[Aib]EGSFTSELATILD[K([19-carboxy-nonadecanoyl]iso-Lys-Peg3-Peg3-
Peg3)]QAARDFIAWLIQQKITD-OH (Compound 35);
(SEQ ID NO: 218)
Hy-H[Aib]EGSFTSELATILD[K(Octadecanoyl)]QAARDFIAWLIQYKITD-OH (Compound 36);
(SEQ ID NO: 219)
Hy-H[Aib]EGTFSSELSTILE[K(Hexadecanoyl-isoGlu)]QASREFIAWLIAYKITE-OH
(Compound 37);
(SEQ ID NO: 220)
Hy-H[Aib]EGTFSSELATILDEQAARDFIAWLIAHKITDkkkkkk([17-carboxy-Heptadecanoyl]-
isoGlu)]-[NH2] (Compound 38);
(SEQ ID NO: 221)
Hy-H[Aib]EGTFTSELATILDEQAARDFIAWLIAHKITDkkkkkk([17-carboxy-Heptadecanoyl]-
isoGlu)]-[NH2] (Compound 39);
(SEQ ID NO: 222)
Hy-H[Aib]EGSFTSELATILDEQAARDFIAWLIEHKITDkkkkkk([17-carboxy-Heptadecanoyl]-
isoGlu)]-[NH2] (Compound 40);
(SEQ ID NO: 223)
Hy-H[Aib]EGTFTSELATILD[K([19-carboxy-nonadecanoyl]-isoGlu)]QAARDFIAWLIQHKITD-
OH (Compound 41);
(SEQ ID NO: 224)
Hy-H[Aib]EGSFTSE[K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-
Peg3)]ATILDEQAARDFIAWLIEHKITD-OH (Compound 42);
(SEQ ID NO: 225)
Hy-H[Aib]EGSFTSELATILD[K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-
Peg3)]KAARDFIAWLIEHKITD-OH (Compound 43);
(SEQ ID NO: 226)
Hy-H[Aib]EGSFTSELATILEG[K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-
Peg3)]AARDFIAWLIEHKITD-OH (Compound 44);
(SEQ ID NO: 227)
Hy-H[Aib]EGSFTSELATILDEQAA[K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-
Peg3)]DFIAWLIEHKITD-OH (Compound 45);
(SEQ ID NO: 228)
Hy-H[Aib]EGTFTSELATILDEQAA[K([19-carboxy-nonadecanoyl]iso-Glu-Peg3-
Peg3)]DFIAWLIEHKITD-OH (Compound 46);
(SEQ ID NO: 229)
Hy-H[Aib]EGTFSSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu-KEK-
Peg3)]QAARDFIAWLIQHKITD-OH (Compound 47);
(SEQ ID NO: 230)
Hy-H[Aib]EGTFSSELATILD[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]QAARDFIAWLIQHKITD-OH (Compound 48);
(SEQ ID NO: 231)
Hy-H[Aib]EGTFSSELATILD[K([17-carboxy-heptadecanoyl]-isoGlu-KEK-
Peg3)]QAARDFIAWLIEHKITD-OH (Compound 49);
(SEQ ID NO: 232)
Hy-H[Aib]EGTFSSELATILD[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]QAARDFIAWLIEHKITD-OH (Compound 50);
(SEQ ID NO: 233)
Hy-H[Aib]EGTFTSELATILD[K([19-carboxy-nonadecanoyl]-isoGlu-
KEK)]QAARDFIAWLIQHKITD-OH (Compound 51);
(SEQ ID NO: 234)
Hy-H[Aib]EGTFTSELATILD[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]QAARDFIAWLIQHKITD-OH (Compound 52);
(SEQ ID NO: 235)
Hy-H[Aib]EGSFTSE[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]ATILDEQAARDFIAWLIEHKITD-OH (Compound 53);
(SEQ ID NO: 236)
Hy-H[Aib]EGTFTSE[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]ATILDEQAARDFIAWLIEHKITD-OH (Compound 54);
(SEQ ID NO: 237)
Hy-H[Aib]EGSFTSE[K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-
Peg3)]ATILDEQAARDFIAWLIEHKITD-OH (Compound 55);
(SEQ ID NO: 238)
Hy-H[Aib]EGTFTSELATILD[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]QAARDFIAWLIEHKITD-OH (Compound 56);
(SEQ ID NO: 239)
Hy-H[Aib]EGSFTSELATILD[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]QAARDFIAWLIEHKITD-OH (Compound 57);
(SEQ ID NO: 240)
Hy-H[Aib]EGSFTSELATILD[K(19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]QAARDFIAWLIAHKITD-OH (Compound 58);
(SEQ ID NO: 241)
Hy-H[Aib]EGSFTSELATILD[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]KAARDFIAWLIEHKITD-OH (Compound 59);
(SEQ ID NO: 242)
Hy-H[Aib]EGSFTSELATILD[K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-
Peg3)]QAARDFIAWLIEHKITD-OH (Compound 60);
(SEQ ID NO: 243)
Hy-H[Aib]EGSFTSELATILEG[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]AARDFIAWLIEHKITD-OH (Compound 61);
(SEQ ID NO: 244)
Hy-H[Aib]EGSFTSELATILDA[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]AARDFIAWLIEHKITD-OH (Compound 62);
(SEQ ID NO: 245)
Hy-H[Aib]EGSFTSELATILDA[K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-
Peg3)]AARDFIAWLIEHKITD-OH (Compound 63);
(SEQ ID NO: 246)
Hy-H[Aib]EGSFTSELATILDEQAA[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]DFIAWLIEHKITD-OH (Compound 64);
(SEQ ID NO: 247)
Hy-H[Aib]EGTFTSELATILDEQAA[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]DFIAWLIEHKITD-OH (Compound 65);
(SEQ ID NO: 248)
Hy-H[Aib]EGSFTSELATILDEQAA[K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-
Peg3)]DFIAWLIEHKITD-OH (Compound 66);
(SEQ ID NO: 249)
Hy-H[Aib]EGTFTSELATILDEQAA[K([19-carboxy-nonadecanoyl]iso-Glu-KEK-Peg3-
Peg3)]DFIAWLIEHKITD-OH (Compound 67);
or
(SEQ ID NO: 250)
Hy-H[Aib]EGSFTSELATILDAKAA[K([19-carboxy-nonadecanoyl]-isoGlu-KEK-
Peg3)]DFIAWLIEHKITD-OH (Compound 68).Join the waitlist — get patent alerts
Track US2023405087A9 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.